|MDACC Study No:||2012-1125 (clinicaltrials.gov NCT No: NCT01744691)|
|Title:||An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with 17p Deletion|
|Principal Investigator:||William G. Wierda|
|Study Description:||The goal of this clinical research study is to learn if PCI-32765 (ibrutinib) |
can help to control CLL and SLL. The safety of this drug will also be studied.
Ibrutinib is designed to stop a protein from working in the cells, which may
cause the cancer cells to die or stop growing.